#USA #Class Action #San Francisco #SEC Claims #Hims & Hers

Hims & Hers Faces Class Action Lawsuit Amid FTC Allegations

Hims & Hers Health, Inc. (NYSE: HIMS) is currently undergoing a tumultuous period as it confronts a class action lawsuit stemming from a serious complaint filed by the Federal Trade Commission (FTC). The FTC's allegations accuse the company of engaging in deceptive practices concerning the handling of sensitive health information, which has left many investors reeling from substantial financial losses.

Background on Hims & Hers Health

Founded in 2017, Hims & Hers Health aims to provide direct-to-consumer telehealth services, specializing in personal and sexual wellness products. The company gained popularity for its mail-order prescriptions and an approachable online consultation model intended to empower users seeking discreet healthcare solutions. However, recent developments have cast a shadow on its reputation and operational integrity.

Allegations from the FTC

On July 29, 2026, the FTC took decisive action against Hims with a comprehensive complaint that has become central to the current class action lawsuit. The commission's claims detail multiple instances of alleged misconduct, including:

1. Improper Health Data Sharing: The FTC asserts that Hims violated privacy assurances by improperly sharing users' health information with third-party advertising entities. This blatant disregard for user privacy underscores the company's failure to uphold its stated protective measures regarding customer data.

2. Misleading Billing Practices: Investors' fears were compounded by accusations that Hims enrolled consumers in automatic subscription billing plans without their informed consent, contravening the Restore Online Shoppers' Confidence Act (ROSCA). Reports indicate that consumers were charged for prescriptions immediately upon completing their intake forms—far sooner than any consultation with a medical provider.

Impact on Investors

The fallout from these allegations has been sharp. Following the FTC's announcement, Hims & Hers experienced a drastic stock price plunge, losing $4.32 (or 14.7%) in value within a single day. This catastrophic drop has erased nearly $970 million from the company’s market capitalization. Investors who believed in the integrity and prospects of Hims & Hers are now grappling with significant financial setbacks.

As the lawsuit unfolds, Hagens Berman, the firm spearheading the class action, has called on investors who have suffered losses to come forward and join the legal battle. They emphasize the need for accountability in the face of what could be perceived as deliberate misleading of investors regarding the safety and efficacy of Hims’ corporate practices.

Next Steps for Affected Investors

Investors who have experienced material losses in the past year are encouraged to file their claims and consider joining the class action lawsuit. The deadline for primary plaintiffs is set for November 2, 2026, giving investors time to prepare and seek potential restitution.

Hagens Berman is also extending its support to whistleblowers who may possess non-public information relevant to the investigation. Participants in the whistleblower program could reap significant rewards should their information contribute to a successful recovery.

In closing, Hims & Hers Health stands at a critical juncture, as the upcoming months will prove pivotal in determining its corporate fate and the financial restitution available to disillusioned investors. As legal proceedings are set in motion, stakeholders must remain vigilant and informed about their options.